Polymer conjugates as anticancer nanomedicines
Top Cited Papers
- 10 August 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 6 (9), 688-701
- https://doi.org/10.1038/nrc1958
Abstract
The transfer of polymer-protein conjugates into routine clinical use, and the clinical development of polymer-anticancer-drug conjugates, both as single agents and as components of combination therapy, is establishing polymer therapeutics as one of the first classes of anticancer nanomedicines. There is growing optimism that ever more sophisticated polymer-based vectors will be a significant addition to the armoury currently used for cancer therapy.Keywords
This publication has 100 references indexed in Scilit:
- Chemotherapy and the war on cancerNature Reviews Cancer, 2005
- Selective anticancer drugsNature Reviews Cancer, 2002
- Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugsJournal of Controlled Release, 2002
- HPMA Copolymers Platinates Containing Dicarboxylato Ligands. Preparation, Characterisation and In Vitro and In Vivo EvaluationJournal of Drug Targeting, 2002
- Mechanisms of anticancer action of HPMA copolymer-bound doxorubicinMacromolecular Symposia, 2001
- A Possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrierEuropean Journal of Cancer, 1999
- Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrierEuropean Journal of Cancer, 1995
- Estrogen modulation of osteoclast lysosomal enzyme secretionJournal of Cellular Biochemistry, 1995
- A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or lightJournal of Biomaterials Science, Polymer Edition, 1994
- Structure and properties of pharmacologically active polymersJournal of Polymer Science: Polymer Symposia, 1975